Prostate cancer is the most common cancer in men. It mainly affects older men and can be treated with surgery, radiation therapy, chemotherapy or hormone therapy. However, all treatments have side effects that limit their use if possible by physicians. Particularly for metastatic prostate cancer that does not respond to any other treatment methods, lutetium-177 PRRT offers hope for patients who want to extend their life span significantly without suffering from severe side effects caused by other therapies such as chemotherapy or hormone therapy. The Federal Institute for Drugs and Medical Devices (BfArM) has approved this relatively new drug since 2018 after successful clinical studies showed its effectiveness over several years of use worldwide https://bookinghealth.com/disease/lutetium-177-psma-therapy/germany
Lutetium-177 is a highly effective and modern therapy to treat prostate cancer.
Lutetium-177 is a highly effective and modern therapy to treat prostate cancer. It is one of the so-called beta emitter peptide receptor radiotherapy (PRRT). Beta particles are emitted by the decay products of radioisotopes. They are more penetrating than x-rays, but less damaging than alpha particles.
The advantages of Lutetium-177 in comparison with conventional methods include its greater accuracy and precision, as well as its capacity to treat deep tumors without affecting surrounding healthy tissue. The treatment produces few side effects because it does not require surgery or radiation oncology procedures such as brachytherapy that can cause damage to surrounding organs or tissues.
It is particularly indicated for patients with metastatic prostate cancer who have already received other treatment options such as hormone therapy and chemotherapy and thus no longer respond to these treatments.
Lutetium-177 is an alternative to hormone therapy and chemotherapy. It is indicated for patients with metastatic prostate cancer who have already received other treatment options such as hormone therapy and chemotherapy and thus no longer respond to these treatments.
In addition, lutetium-177 can be used together with other therapies such as radiotherapy or surgery to increase their effectiveness.
Lutetium-177 therapy therefore offers men with prostate carcinoma, who are no longer treating hormone therapy, an alternative method of treatment that can extend their life significantly.
Lutetium-177 is a relatively new drug that has been shown to be highly effective in the treatment of prostate carcinoma. It is particularly indicated for patients with metastatic prostate cancer who have already received other treatments such as hormone therapy and chemotherapy.
Lutetium-177 therapy therefore offers men with prostate carcinoma, who are no longer treating hormone therapy, an alternative method of treatment that can extend their life significantly.
This relatively new drug was approved in Germany by the Federal Institute for Drugs and Medical Devices (BfArM) in 2018 after successful clinical studies.
Lutetium-177 is a relatively new drug that was approved for use in Germany by the Federal Institute for Drugs and Medical Devices (BfArM) in 2018. It's used to treat prostate cancer, but it's not clear how effective it is compared with other treatments available.
In clinical studies, lutetium-177 was found to be safe and effective for treating prostate cancer. The FDA approved its use based on these findings as well as clinical data from patients who had received treatment with lutetium-177 outside of the United States between 2014 and 2016.
However, it's more expensive than other treatments — costing about $100,000 per patient — which may make it difficult for some people to afford the treatment plan required during their lifetime.
Lutetium-177 is a so-called beta emitter peptide receptor radiotherapy (PRRT).
Lutetium-177 is a so-called beta emitter peptide receptor radiotherapy (PRRT). This form of radiation therapy works by delivering radioactive lutetium-177 to cancer cells, which the body then absorbs. Once the cancer cells have absorbed the radioactive material, it travels through the bloodstream to other parts of your body. The radiation released by lutetium-177 kills cancer cells and prevents them from growing or spreading.
Lutetium-177 PRRT has been approved in Europe as a treatment for prostate cancer that has spread or cannot be treated effectively with surgery or other therapies. In Germany, however, it's also approved for early stage prostate cancer patients who can't tolerate other treatments such as surgery or radiation therapy due to age or medical history.
The radioactive isotope is attached to a substance that specifically binds to prostate cancer cells.
Lutetium-177-PSMA therapy is a way to treat prostate cancer by delivering a radioactive isotope directly to the tumor cells. The radioactive isotope is attached to a substance that specifically binds to prostate cancer cells. This means that the target substance has an affinity for the PSMA receptor, which is present on most malignant tumors but not healthy tissues. The radioactive isotope and the target substance are linked together with a chemical bond called chelation.
Lutetium-177 damages the tumor cells from the inside and thus eliminates them slowly but surely.
Lutetium-177 is a beta emitter, which means that it emits very energetic beta particles. These particles can penetrate deep into the tissue and damage the DNA of the tumor cells. This damage leads to cell death.
Since the drug specifically targets tumor cells, healthy cells are hardly attacked by the beta radiation emitted by lutetium-177.
Lutetium-177 is a highly effective and modern therapy to treat prostate cancer. This therapy is particularly indicated for patients with metastatic prostate cancer who have already received other treatment options such as hormone therapy and chemotherapy. The drug specifically targets tumor cells, so healthy cells are hardly attacked by the beta radiation emitted by lutetium-177.
Unlike chemotherapy, which often causes severe side effects due to immune system impairment, the patient's immune status does not change during the lutetium-177 treatment.
Lutetium-177 is a non-invasive therapy that does not change the immune status of the patient. This is why it is particularly suitable for patients with weakened immune systems, such as those undergoing chemotherapy or suffering from AIDS. Lutetium-177 thus provides an alternative to conventional treatment methods, which can have severe side effects due to immune system impairment.
Lutetium-177 PRRT is a noninvasive and highly specific treatment for prostate cancer
Lutetium-177 PRRT is a noninvasive and highly specific treatment for prostate cancer. Lutetium-177 is attached to a substance that specifically binds to prostate cancer cells, which allows it to destroy them from the inside. The therapy usually takes place in several sessions over several weeks or months.
Conclusion
Lutetium-177 PRRT is the first drug in Germany approved for the treatment of prostate cancer. It is a modern, highly effective therapy that has already proven its worth in clinical studies. The drug destroys tumor cells from within and can be used with other therapies such as hormone therapy or chemotherapy. Therefore, patients no longer respond to these treatments are offered an alternative method of treatment that can extend their life significantly. Lutetium-177 therapy is therefore a valuable option for men who have prostate carcinoma but are no longer responding to other treatments such as hormone therapy or chemotherapy.
